Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD44 | P16070 | 1/20 | 0.37 |
| ▸ | DHFR | P00374 | 1/20 | 0.37 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 3/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | GLP1R | P43220 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.33 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.33 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15537755 | 0.83 | CD44 (0.41) | CD44DHFRLMNAKDM4EALDH1A1 | |
| SCHEMBL24455092 | 0.83 | CD44 (0.41) | CD44DHFRSLC9A1LMNAKDM4E | |
| SCHEMBL8478664 | 0.83 | CD44 (0.46) | CD44LMNAKDM4EALDH1A1CYP3A4 | |
| SCHEMBL6844950 | 0.81 | LMNA (0.38) | CD44LMNAALDH1A1CYP3A4HTT | |
| SCHEMBL15538252 | 0.79 | LMNA (0.41) | CD44SLC9A1LMNAKDM4EALDH1A1 | |
| SCHEMBL16501095 | 0.79 | KHK (0.44) | CD44DHFRLMNAKDM4EALDH1A1 | |
| SCHEMBL10144270 | 0.79 | SLC9A1 (0.37) | CD44DHFRSLC9A1LMNAKDM4E | |
| SCHEMBL15537882 | 0.79 | LMNA (0.41) | CD44DHFRLMNAKDM4EALDH1A1 | |
| SCHEMBL15538631 | 0.76 | CRHR1 (0.34) | CD44LMNAKDM4EALDH1A1GLP1R | |
| SCHEMBL17442646 | 0.76 | SMN1; SMN2 (0.37) | CD44DHFRSLC9A1KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250282792-A1 | GONADOTROPIN-RELEASING HORMONE RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO | NEUROCRINE BIOSCIENCES, INC. | 2025-09-11 | — | — | US | disclosed |
| US-11713324-B2 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto | NEUROCRINE BIOSCIENCES, INC. (US) | 2023-08-01 | — | — | US | disclosed |
| US-20210284653-A1 | GONADOTROPIN-RELEASING HORMONE RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO | NEUROCRINE BIOSCIENCES, INC. | 2021-09-16 | — | — | US | disclosed |
| US-10941159-B2 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto | NEUROCRINE BIOSCIENCES, INC. (US) | 2021-03-09 | — | — | US | disclosed |
| US-20200095259-A1 | GONADOTROPIN-RELEASING HORMONE RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO | NEUROCRINE BIOSCIENCES, INC. | 2020-03-26 | — | — | US | disclosed |
| US-10336769-B2 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto | NEUROCRINE BIOSCIENCES, INC. (US) | 2019-07-02 | — | — | US | disclosed |
| US-20170320888-A1 | GONADOTROPIN-RELEASING HORMONE RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO | NEUROCRINE BIOSCIENCES, INC. | 2017-11-09 | — | — | US | disclosed |
| EP-2855455-B1 | TRIAZOLO COMPOUNDS AS PDE10 INHIBITORS | HOFFMANN LA ROCHE (CH) | 2017-11-08 | — | — | EP | disclosed |
| US-9422310-B2 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto | NEUROCRINE BIOSCIENCES, INC. (US) | 2016-08-23 | — | — | US | disclosed |
| US-9394311-B2 | Triazolo compounds as PDE10 inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2016-07-19 | — | — | US | disclosed |
| US-20100099684-A1 | Quinuclidine Compounds as Alpha-7 Nicotinic Acetylcholine Receptor Ligands | BRISTOL-MYERS SQUIBB COMPANY | 2010-04-22 | — | — | US | disclosed |
| EP-2155194-A1 | GONADOTROPIN-RELEASING HORMONE RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO | NEUROCRINE BIOSCIENCES, INC. (US) | 2010-02-24 | — | — | EP | disclosed |
| WO-2008124610-A1 | GONADOTROPIN-RELEASING HORMONE RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO | NEUROCRINE BIOSCIENCES, INC. (US) | 2008-10-16 | — | — | WO | disclosed |
| WO-2008124614-A1 | GONADOTROPIN-RELEASING HORMONE RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO | NEUROCRINE BIOSCIENCES, INC. (US) | 2008-10-16 | — | — | WO | disclosed |
| US-5112989-A | Process for producing unsaturated mono and dicarboxylic acid imide compound | MATSUSHITA ELECTRIC WORKS LTD. (JP) | 1992-05-12 | — | — | US | disclosed |
| EP-0387381-A1 | Process for producing unsaturated dicarboxylic acid imide compound | MATSUSHITA ELECTRIC WORKS, LTD. (JP) | 1990-09-19 | — | — | EP | disclosed |
| EP-0118093-A1 | Trichloroacryloyl urea derivatives, process for their preparation and their use as fungicides in agriculture and horticulture | NIHON TOKUSHU NOYAKU SEIZO K.K. (JP) | 1984-09-12 | — | — | EP | disclosed |
| EP-0031257-B1 | PYRIDYLANILINES | ISHIHARA SANGYO KAISHA LTD. (JP) | 1984-08-15 | — | — | EP | disclosed |
| US-4331670-A | PESTICIDES | ISHIHARA SANGYO KAISHA, LTD. (JP) | 1982-05-25 | — | — | US | disclosed |
| EP-0031257-A2 | Pyridylanilines | ISHIHARA SANGYO KAISHA LTD. (JP) | 1981-07-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100099684-A1 | Quinuclidine Compounds as Alpha-7 Nicotinic Acetylcholine Receptor Ligands | CHRNA7, CHRNA5, CHRNA6 | CD44 4101/4885DHFR 2696/4885SLC9A1 1459/4885 |
| US-20170320888-A1 | GONADOTROPIN-RELEASING HORMONE RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO | GNRHR, GHRHR, LHCGR | CD44 4649/4885DHFR 3549/4885SLC9A1 1242/4885 |
| US-20250282792-A1 | GONADOTROPIN-RELEASING HORMONE RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO | GNRHR, GHRHR, LHCGR | CD44 4649/4885DHFR 3549/4885SLC9A1 1242/4885 |
| US-11713324-B2 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto | GNRHR, GHRHR, LHCGR | CD44 4649/4885DHFR 3549/4885SLC9A1 1242/4885 |
| US-20210284653-A1 | GONADOTROPIN-RELEASING HORMONE RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO | GNRHR, GHRHR, LHCGR | CD44 4649/4885DHFR 3549/4885SLC9A1 1242/4885 |
| US-10941159-B2 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto | GNRHR, GHRHR, LHCGR | CD44 4649/4885DHFR 3549/4885SLC9A1 1242/4885 |
| US-20200095259-A1 | GONADOTROPIN-RELEASING HORMONE RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO | GNRHR, GHRHR, LHCGR | CD44 4649/4885DHFR 3549/4885SLC9A1 1242/4885 |
| US-10336769-B2 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto | GNRHR, GHRHR, LHCGR | CD44 4649/4885DHFR 3549/4885SLC9A1 1242/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.